Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Edderd who wrote (4334)	1/5/1998 8:03:00 PM
From: Edderd	Read Replies (3) \| Respond to of 23519

December 29, 1997 Dear HealthCare Professional: Beginning in February, through broadcast television advertising, major sports event sponsorship and nationwide magazine advertising, men with erectile dysfunction (ED) will learn that they're not alone with this disorder and expert help is as close as the nearest urologist. The campaign will encourage patients to see a physician for proper diagnosis and treatment. Since some primary care physicians may be required by managed care protocols to treat the patient directly, we are educating them on prevalence, etiologies, treatment options and that the urologist is the ED specialist. The enclosed brochure includes examples of the direct-to-consumer advertising messages men will be hearing about ED and MUSE (alprostadil) urethral suppository therapy. We want you to be informed before the nationwide campaign commences. The MUSE U.S. clinical trial experience has recently been confirmed from a 3-month, double- bhnd, placebo-controlled trial conducted in five European countries. Of the 248 patients that entered the study, 64% were successful in obtaining an erection sufficient for intercourse.1 The most frequently reported adverse effect, urethral pain/burning, was reported by 7% of study patients in clinic. In this study, the percentage distribution of dose strengths selected by in-clinic responders was 65% on 1000 mcg, 17% on 500 mcg, 13% on 250 mcg and only 5% on 125 mcg. Once the MUSE advertising begins in February, you may expect substantially increased patient visits for ED. We hope to help your practice grow with this campaign. We will soon be sending you campaign-related patient education materials for your office to help patients associate the national campaign with your practice in this important, sensitive area. Yours sincerely, Alfred P. Spivack, MD Director Medical Services PS. MUSE is the local solution for a local probleri~with a 5- to 10-minute onset and few systemic side effects. For more information, call 1-888-345-MUSE to speak with our Medical Department. REFERENCE: 1. Amar Er, Ct ai. "Intemational multicenter, doubte-bhnd, placebocontrolied trids of transurethras aiprostadil in men with chronic erectile dysfunction" Abstract presented at the 6th Biennial Asia-Pactic Society of Impotence Reaearch Meeting; October 22-26, i997~ CALLS FOR SUPPORT Get ready for the MUSE direct-to-consumer advertising campaign in your office. When more patients start coming to you with questions, you'll have the answers. VIVUS offers a complete range of free patient education and support materials, including videotapes, brochures and the Right Start Program, a confidential service that helps patients begin MUSE treatment. First scan to thread experience for me. Looking good. Above arrived today but I dont have the full color brochure ready for transmission. Ed